Therefore, targeting EGFR mutations‐driven immune suppression to reverse DC function would be a promising strategy to enhance anti‐tumor immunity of CD8+ T cells and improve the efficacy of ICIs in this patient population. This evidence concerns the gene EGFR and neoplasm.